TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$94 Million


Initial Public Offering

Bookrunner, February 2024


Metagenomi, Inc (“Metagenomi” or the “Company”) (NASDAQ: MGX) is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The Company is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to discover and develop a suite of novel editing tools capable of correcting genetic mutations. Metagenomi’s comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (“CRISPR”)-associated transposases (“CASTs”)). The Company is taking a stepwise approach deploying its genome editing toolbox to develop potentially curative therapies for patients. The Company’s lead programs are selected to both address important diseases and to establish new standards in targetability, precision, efficiency, and scope of editing capabilities.